Literature DB >> 2293218

Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers.

E K Hussey1, G E Dukes, J A Messenheimer, K L Brouwer, K H Donn, T F Krol, L J Hak.   

Abstract

The protein binding and pharmacokinetics of diazepam, ACC-9653 (a phenytoin prodrug), and phenytoin were evaluated in nine healthy male volunteers following administration of diazepam and ACC-9653, alone or concomitantly, in a randomized crossover design. No significant differences were observed in the fraction unbound or pharmacokinetic parameters of ACC-9653, phenytoin, or diazepam when ACC-9653 was administered alone compared to concomitant administration with diazepam. The phenytoin fraction unbound increased significantly with increased concentrations of ACC-9653, indicating displacement of phenytoin from its binding sites by ACC-9653. ACC-9653 also demonstrated concentration dependent binding. The lack of a significant pharmacokinetic drug interaction between ACC-9653 and diazepam suggests that these drugs may be safely administered together, although this conclusion should be confirmed in the intended patient population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293218     DOI: 10.1023/a:1015940527815

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  High-performance liquid chromatographic determination of benzodiazepines in human plasma.

Authors:  R R Brodie; L F Chasseaud; T Taylor
Journal:  J Chromatogr       Date:  1978-03-21

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

3.  Plasma protein binding of tricyclic anti-depressants in man.

Authors:  O Borgå; D L Azarnoff; G P Forshell; F Sjöqvist
Journal:  Biochem Pharmacol       Date:  1969-09       Impact factor: 5.858

4.  Serum protein binding of diazepam and its displacement by valproic acid in vitro.

Authors:  S Dhillon; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

5.  Current concepts in neurology: management of status epilepticus.

Authors:  A V Delgado-Escueta; C Wasterlain; D M Treiman; R J Porter
Journal:  N Engl J Med       Date:  1982-06-03       Impact factor: 91.245

6.  Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations.

Authors:  T Zysset; T Zeugin
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

Review 7.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

8.  Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  J Pharmacol Exp Ther       Date:  1976-10       Impact factor: 4.030

Review 9.  Recent developments in the diagnosis and therapy of epilepsy.

Authors:  J Engel; A S Troupin; P H Crandall; M B Sterman; C G Wasterlain
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

10.  Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration.

Authors:  S Dhillon; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  2 in total

Review 1.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.

Authors:  Yushi Inoue; Naotaka Usui; Tadayuki Hiroki; Kenji Shimizu; Susumu Kobayashi; Shigeki Shimasaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-09-12       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.